Medical technology company Becton Dickinson announced on 28 March 2013 that FDA had approved the first drug in its line of prefilled generic injectables. This can only be good news for FDA who has been fighting to alleviate drug shortages in the US, most of which are due to shortages in generic sterile injectables.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- FDA approves first interchangeable ranibizumab biosimilar Ranluspec
- EMA recommends approval for biosimilar Denosumab Ascend and pegfilgrastim Nylaspeg
- FDA approves Ennumo as eighth pegfilgrastim biosimilar
- FDA approves first interchangeable golimumab biosimilars Immgolis and Immgolis Intri
Investigación
- Biosimilar interchangeability: a necessary fix, but not a silver bullet
- EULAR 2025 RA guidelines streamlined as biosimilar expansion reshapes treatment sequencing
- Adopción de biosimilares en Chile: ¿Por qué se demora?
- La jeringa precargada del biosimilar de aflibercept (AVT06) promete inyecciones oculares más seguras y rápidas
- MORE EDITORIAL SECTIONS
- Search




Post your comment